Adaptive Platform Treatment Trial for Outpatients with COVID-19 (ACTIV-2)
Sponsor: |
National Institute of Allergy and Infectious Diseases NIAID |
Enrolling: |
Male and Female Patients |
Study Length: |
18 Months |
Clinic Visits: |
11 |
IRB Number: |
AAAT6083 |
U.S. Govt. ID: |
NCT04518410 |
Contact: |
Bronx Prevention Center: 347-590-7280 / lp2907@cumc.columbia.edu |
This study enrolls people recently diagnosed with COVID-19, who are not currently in the hospital. The study tests several different investigational medicines to see if they are safe and can help adults with COVID-19 get better, with the goal of quickly determining those that are safe and effective. Help us to rise above COVID-19!
This study is closed
Investigator
Ellen Morrison, MD, MPH
Are you having any symptoms of COVID-19 (i.e., fever, body aches, chills, loss of taste/smell, etc.)? |
Yes |
No |
Have you been hospitalized for COVID-19? |
Yes |
No |
Are you pregnant or breastfeeding? If N/A, select No. |
Yes |
No |